cilostazol has been researched along with Angiogenesis, Pathologic in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 7.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 5.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Two PDE inhibitors including cilostazol a PDE3 inhibitor (40 and 400 mg/kg), and pentoxifylline (PTX), a PDE 1-5 inhibitor (50 and 500 mg/kg) were used for a period of 7 days to inhibit angiogenesis, inflammation, and fibrosis in a murine model of sponge-induced peritoneal adhesion." | 3.75 | Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. ( Andrade, SP; Campos, PP; Mendes, JB; Rocha, MA, 2009) |
| "Cilostazol is a phosphodiesterase III inhibitor increases adenosine 3', 5'-cyclic monophosphate (cyclic AMP) level which inhibits hepatic stellate cell activation." | 1.42 | Cilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats. ( Abdel Kawy, HS, 2015) |
| "Stroke is the major cause of death and decrease in the activities of daily living." | 1.40 | Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. ( Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Liu, N; Liu, W; Omote, Y; Yamashita, T, 2014) |
| "Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES." | 1.39 | Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. ( Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Tseng, SY | 3 |
| Chang, HY | 2 |
| Li, YH | 3 |
| Chao, TH | 3 |
| Kan, CD | 1 |
| Wang, JN | 1 |
| Li, WP | 1 |
| Lin, SH | 1 |
| Chen, WL | 1 |
| Hsu, YP | 1 |
| Yeh, CS | 1 |
| Kwon, JS | 1 |
| Kim, YS | 1 |
| Cho, HH | 1 |
| Kee, HJ | 1 |
| Hong, MH | 1 |
| Kang, WS | 1 |
| Jeong, HY | 1 |
| Jeong, MH | 1 |
| Ahn, Y | 1 |
| Omote, Y | 1 |
| Deguchi, K | 1 |
| Kono, S | 1 |
| Liu, N | 1 |
| Liu, W | 1 |
| Kurata, T | 1 |
| Yamashita, T | 1 |
| Ikeda, Y | 1 |
| Abe, K | 1 |
| Chen, IC | 1 |
| Tsai, YS | 1 |
| Huang, YY | 1 |
| Liu, PY | 1 |
| Ou, HY | 1 |
| Wu, HL | 1 |
| Cho, CL | 1 |
| Tsai, LM | 1 |
| Chen, JH | 1 |
| Kim, HY | 1 |
| Park, SY | 1 |
| Lee, SW | 1 |
| Lee, HR | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 1 |
| Kim, CD | 1 |
| Abdel Kawy, HS | 1 |
| Mendes, JB | 1 |
| Campos, PP | 1 |
| Rocha, MA | 1 |
| Andrade, SP | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Nishimoto, M | 1 |
| Sakaguchi, M | 1 |
| Kirimura, K | 1 |
| Yuda, A | 1 |
| Miyazaki, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease[NCT02174939] | Phase 4 | 300 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease[NCT02194686] | Phase 4 | 71 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for cilostazol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease.
Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth | 2014 |
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease.
Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth | 2014 |
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease.
Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth | 2014 |
Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease.
Topics: Biomarkers; Cell Movement; Cell Proliferation; Cilostazol; Collateral Circulation; Double-Blind Meth | 2014 |
8 other studies available for cilostazol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cilostazol; Diabetes Me | 2022 |
Clinical ultrasound stimulating angiogenesis following drug-release from polymersomes on the ischemic zone for peripheral arterial occlusive disease.
Topics: Angiogenesis Inducing Agents; Animals; Arterial Occlusive Diseases; Bronchodilator Agents; Cilostazo | 2018 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucos | 2013 |
Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation.
Topics: Animals; Antigens; Aspirin; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Disease Models, An | 2014 |
Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Cells, Cultured; Cilostazol; Fibroblasts; H | 2014 |
Cilostazol attenuates cholestatic liver injury and its complications in common bile duct ligated rats.
Topics: Actins; Animals; Cholestasis; Cilostazol; Common Bile Duct; Dose-Response Relationship, Drug; Hemogl | 2015 |
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice.
Topics: Animals; Cilostazol; Disease Models, Animal; Fibrosis; Inflammation; Male; Mice; Mice, Inbred BALB C | 2009 |
Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes.
Topics: Angiotensin II; Animals; Blood Vessels; Chymases; Cilostazol; Dogs; In Vitro Techniques; Neovascular | 2001 |